RecruitingNot ApplicableNCT05577819

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients With Heart Failure With Preserved Ejection Fraction


Sponsor

Massachusetts General Hospital

Enrollment

515 participants

Start Date

Oct 2, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.


Eligibility

Min Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how common a type of heart failure called ATTR amyloidosis cardiomyopathy is among patients with heart failure with preserved ejection fraction (HFpEF). HFpEF means the heart pumps normally but is too stiff. ATTR is caused by a protein buildup in the heart and is often underdiagnosed. **You may be eligible if...** - You are 65 or older - You have a confirmed diagnosis of HFpEF (a type of heart failure where the heart's pumping strength is relatively normal) **You may NOT be eligible if...** - You have end-stage kidney disease on dialysis - You have a history of reduced ejection fraction heart failure (below 40%) outside of specific acute events - You had a negative ATTR scan (99mTc-pyrophosphate) within the past year - You have already been diagnosed with amyloidosis - You have severe uncorrected heart valve disease - You cannot lie flat for 15 minutes for the scan Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TEST99mTc-pyrophosphate Scintigraphy

Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer


Locations(1)

Massachusetts General Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05577819


Related Trials